A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections

被引:2
|
作者
Kim, Minyoung Kevin [1 ]
Chen, Qingquan [1 ]
Echterhof, Arne [1 ]
Pennetzdorfer, Nina [1 ]
Mcbride, Robert C. [1 ]
Banaei, Niaz [1 ]
Burgener, Elizabeth B. [2 ]
Milla, Carlos E. [2 ]
Bollyky, Paul L. [1 ]
机构
[1] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pediat, Ctr Excellence Pulm Biol, Stanford, CA USA
基金
美国国家卫生研究院;
关键词
HOST-RANGE; STAPHYLOCOCCUS-AUREUS; PHAGE THERAPY; IN-VITRO; RESISTANCE; DISCOVERY;
D O I
10.1038/s41467-024-53994-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages. While phage cocktails targeting all possible bacterial receptors could theoretically confer broad coverage, the extensive diversity of bacteria and the complexity of phage-phage interactions render this approach challenging. Here, using screening protocols for identifying "complementarity groups" of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent the emergence of bacterial resistance. We also discover characteristic interactions between phage complementarity groups and particular antibiotic classes, facilitating the prediction of phage-antibiotic as well as phage-phage interactions. Using this strategy, we create three phage-antibiotic cocktails, each demonstrating efficacy against >= 96% of 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, and demonstrate comparable efficacy in an in vivo wound infection model. We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate their utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for the development of effective, broad-spectrum phage-antibiotic cocktails, paving the way for off-the-shelf phage-based therapeutics to combat multidrug-resistant bacterial infections. The application of phage therapy for multidrug-resistant infections is mainly limited to personalized therapy due to the narrow host range of individual phages. Here, Kim et al. identify groups of phages that use non-redundant receptors, and present a blueprint for the development of effective, broad-spectrum phage-antibiotic combinations.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa
    Santamaria-Corral, Guillermo
    Senhaji-Kacha, Abrar
    Broncano-Lavado, Antonio
    Esteban, Jaime
    Garcia-Quintanilla, Meritxell
    ANTIBIOTICS-BASEL, 2023, 12 (07):
  • [2] The Potential of Bacteriophage-Antibiotic Combination Therapy in Treating Infections with Multidrug-Resistant Bacteria
    Osman, Abdul-Halim
    Kotey, Fleischer C. N.
    Odoom, Alex
    Darkwah, Samuel
    Yeboah, Raphael K.
    Dayie, Nicholas T. K. D.
    Donkor, Eric S.
    ANTIBIOTICS-BASEL, 2023, 12 (08):
  • [3] Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus
    Kebriaei, Razieh
    Lev, Katherine
    Morrisette, Taylor
    Stamper, Kyle C.
    Abdul-Matakabbir, Jacinda C.
    Lehman, Susan M.
    Morales, Sandra
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [4] Bacteriophage precision drug against bacterial infections
    Sector Reform Cell, Directorate of Health Services, Thiruvananthapuram 695 035, India
    Curr. Sci., 2006, 5 (631-633):
  • [5] Bacteriophage precision drug against bacterial infections
    Sandeep, K
    CURRENT SCIENCE, 2006, 90 (05): : 631 - 633
  • [6] Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination
    Kebriaei, Razieh
    Lev, Katherine L.
    Shah, Rahi M.
    Stamper, Kyle C.
    Holger, Dana J.
    Morrisette, Taylor
    Coyne, Ashlan J. Kunz
    Lehman, Susan M.
    Rybak, Michael J.
    MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [7] Bacteriophage-antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model
    Wang, Lei
    Tkhilaishvili, Tamta
    Andres, Beatriz Bernal
    Trampuz, Andrej
    Moreno, Mercedes Gonzalez
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (06)
  • [8] Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler
    Van Nieuwenhuyse, Brieuc
    Van der Linden, Dimitri
    Chatzis, Olga
    Lood, Cedric
    Wagemans, Jeroen
    Lavigne, Rob
    Schroven, Kaat
    Paeshuyse, Jan
    de Magnee, Catherine
    Sokal, Etienne
    Stephenne, Xavier
    Scheers, Isabelle
    Rodriguez-Villalobos, Hector
    Djebara, Sarah
    Merabishvili, Maya
    Soentjens, Patrick
    Pirnay, Jean-Paul
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [9] Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler
    Brieuc Van Nieuwenhuyse
    Dimitri Van der Linden
    Olga Chatzis
    Cédric Lood
    Jeroen Wagemans
    Rob Lavigne
    Kaat Schroven
    Jan Paeshuyse
    Catherine de Magnée
    Etienne Sokal
    Xavier Stéphenne
    Isabelle Scheers
    Hector Rodriguez-Villalobos
    Sarah Djebara
    Maya Merabishvili
    Patrick Soentjens
    Jean-Paul Pirnay
    Nature Communications, 13
  • [10] Lactoferrin: An Effective Weapon in the Battle Against Bacterial Infections
    Avalos-Gomez, Christian
    Ramirez-Rico, Gerardo
    Ruiz-Mazon, Lucero
    Sicairos, Nidia Leon
    Serrano-Luna, Jesus
    de la Garza, Mireya
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (40) : 3243 - 3260